These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 12700894

  • 1. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
    Girgert R, Wittrock J, Pfister S, Schweizer P.
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
    [Abstract] [Full Text] [Related]

  • 2. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J, Schweizer P, Girgert R.
    Anticancer Res; 2002 Apr; 22(6C):4205-9. PubMed ID: 12553057
    [Abstract] [Full Text] [Related]

  • 3. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 07; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 5. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 07; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 6. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.
    Leukemia; 2003 Feb 07; 17(2):451-7. PubMed ID: 12592346
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway.
    Law BK, Nørgaard P, Gnudi L, Kahn BB, Poulson HS, Moses HL.
    J Biol Chem; 1999 Feb 19; 274(8):4743-8. PubMed ID: 9988711
    [Abstract] [Full Text] [Related]

  • 8. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM.
    Oncogene; 2000 Nov 16; 19(48):5525-33. PubMed ID: 11114730
    [Abstract] [Full Text] [Related]

  • 10. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC.
    Oncogene; 2003 Feb 27; 22(8):1124-34. PubMed ID: 12606940
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
    Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM.
    Blood; 1999 Oct 01; 94(7):2469-76. PubMed ID: 10498620
    [Abstract] [Full Text] [Related]

  • 12. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 01; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM, Lau N, Guha A.
    Oncogene; 1999 Dec 09; 18(52):7514-26. PubMed ID: 10602510
    [Abstract] [Full Text] [Related]

  • 14. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ.
    Prostate; 2005 Jan 01; 62(1):69-82. PubMed ID: 15389805
    [Abstract] [Full Text] [Related]

  • 15. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW.
    Leukemia; 2003 Aug 01; 17(8):1508-20. PubMed ID: 12886237
    [Abstract] [Full Text] [Related]

  • 16. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26802-6. PubMed ID: 7592920
    [Abstract] [Full Text] [Related]

  • 17. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W, Lebowitz PF, Prendergast GC.
    Mol Cell Biol; 1999 Mar 10; 19(3):1831-40. PubMed ID: 10022870
    [Abstract] [Full Text] [Related]

  • 18. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
    Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, Favre G.
    Endocrinology; 2003 Mar 10; 144(3):989-98. PubMed ID: 12586776
    [Abstract] [Full Text] [Related]

  • 19. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.
    Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ.
    Mol Cell Biol; 2000 Jan 10; 20(1):139-48. PubMed ID: 10594016
    [Abstract] [Full Text] [Related]

  • 20. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
    Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G.
    Radiat Res; 1999 Oct 10; 152(4):404-11. PubMed ID: 10477917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.